Amgen: FDA Okays Adding Positive OS Data From Phase 3 Aspire Trial To Kyprolis

Amgen Inc. (AMGN) said that the U.S. Food and Drug Administration has approved the supplemental New Drug Application or sNDA to add the positive overall survival (OS) data from the Phase 3 ASPIRE trial to the U.S. Prescribing Information for Kyprolis, or carfilzomib.

from RTT - Biotech https://ift.tt/2JCTMls
via IFTTT